867 related articles for article (PubMed ID: 19665644)
1. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
2. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
[TBL] [Abstract][Full Text] [Related]
3. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
4. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
JAMA Intern Med; 2013 Aug; 173(15):1407-14. PubMed ID: 23817631
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
[TBL] [Abstract][Full Text] [Related]
6. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
7. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
[TBL] [Abstract][Full Text] [Related]
8. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
9. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
BMC Med; 2015 Sep; 13():247. PubMed ID: 26420684
[TBL] [Abstract][Full Text] [Related]
10. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
11. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
[TBL] [Abstract][Full Text] [Related]
14. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
16. Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Levitsky A; Forslind K; van Vollenhoven RF;
Scand J Rheumatol; 2015; 44(5):348-53. PubMed ID: 25992914
[TBL] [Abstract][Full Text] [Related]
17. Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
Miller H; Wallman JK; Petersson IF; Saevarsdottir S; Söderling J; Ernestam S; Askling J; van Vollenhoven R; Neovius M
Rheumatology (Oxford); 2021 May; 60(5):2217-2222. PubMed ID: 33179071
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
